Request Demo

Last update 27 Feb 2026

Trazodone Hydrochloride

Last update 27 Feb 2026

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

SummaryTrazodone, a small molecule drug, targets the serotonin transporter and acts as a serotonin reuptake inhibitor. Although approved for treating several conditions, including major depressive disorder, diabetic neuropathies, sleep initiation and maintenance disorders, and premature ejaculation, the drug's mechanism of action remains elusive. Angelini Pharma was the first to approve the drug for use in December 1981. By increasing serotonin levels in the brain, Trazodone hydrochloride reduces symptoms of depression and improves mood. Additionally, the drug has sedative properties that make it effective in treating sleep disorders. However, Trazodone may produce unwanted side effects such as dizziness, drowsiness, and dry mouth and interact with other medications, resulting in unwanted consequences.

Drug Type

Small molecule drug

Synonyms

Oleptro, Trazodone, Trazodone HCl

+ [17]

Target

5-HT2 receptor x SERT

Action

antagonists

Mechanism

5-HT2 receptor antagonists(Serotonin 2 (5-HT2) receptor antagonists), Serotonin reuptake inhibitors

Therapeutic Areas

Nervous System DiseasesEndocrinology and Metabolic DiseaseOther Diseases+ [1]

Active Indication

Depressive Disorder, MajorDepressive DisorderDiabetic peripheral neuropathy+ [2]

Inactive Indication

Anxiety DisordersAutistic DisorderDiabetic peripheral neuropathic pain+ [1]

Originator Organization

Angelini Pharma, Inc.

Active Organization

Angelini Pharma, Inc.

Shenyang Funing Pharmaceutical Co Ltd.

Aziende Chimiche Riunite Angelini Francesco - A.C.R.A.F. - SpA

+ [5]

Inactive Organization

Zhaoke Pharmaceutical (Hefei) Co., Ltd.

Pragma Pharmaceuticals LLC

Lee's Pharmaceutical Holdings Ltd.

License Organization-

Drug Highest PhaseApproved

First Approval Date

United States (24 Dec 1981),

Depressive Disorder, Major

RegulationOrphan Drug (United States)

Structure/Sequence

Molecular FormulaC19H23Cl2N5O

InChIKeyOHHDIOKRWWOXMT-UHFFFAOYSA-N

CAS Registry25332-39-2

143

Clinical Trials associated with Trazodone Hydrochloride

NCT07210606

/ Not yet recruitingPhase 4IIT

Central Apnea in Heart Failure: Physiological Mechanisms to Inform Treatment

Central sleep apnea (CSA) is common in patients with heart failure and those using opioid analgesics. Unfortunately, effective treatment of central apnea remains elusive, pressure therapy given the modest efficiency of positive airway pressure therapy. The focus of this proposal is to identify mechanistic pathways to guide future therapeutic interventions for central sleep apnea based on the strong premise that multi-modality therapy will normalize respiration and hence mitigate adverse long-term consequences of CSA. The investigators' proposed studies will test combination therapies, including positive airway pressure (PAP) plus a pharmacological agent who have heart failure or are using opioid analgesics. The investigators anticipate that findings will inform future clinical trials to improve care and quality of life among Veterans suffering from central sleep apnea, which remains difficult to treat using existing approaches.

Start Date01 Oct 2026

Sponsor / Collaborator

VA Office of Research and Development

NCT07136415

/ Not yet recruitingPhase 4IIT

CELESTE: Comparative Effectiveness Study of behavioraL and Drug-rElated inSomnia Therapies for pEri- and Post-menopausal People

The goal of this clinical trial is to learn how three current insomnia therapies (trazodone, daridorexant, cognitive behavioral therapy for insomnia) compare with each other in peri- and post-menopausal women. It will also learn about the safety of the treatments. The main questions it aims to answer are:
Which commonly used insomnia therapies are most effective and safe for improving insomnia symptoms in peri- and post-menopausal people?
How well do the treatments work for people from different backgrounds, who are at different stages of menopause, and who have different conditions common during menopause (e.g., sleep apnea, mood disturbance, etc.)?
What medical problems do participants have when using these treatments?
Participants will:
Be asked to take trazodone every night, take daridorexant every night, or participate in an online behavioral program for insomnia, for a total of 12 months.
Participate in a total of one in-person visit and 6 virtual visits (phone calls) over the 12 months.
Wear (and keep) a Fitbit and fill out a daily sleep diary for at least 4 weeks over the 12 months.
Fill out online surveys 5 times over the 12 months.

Start Date01 Feb 2026

Sponsor / Collaborator

The Brigham & Women's Hospital, Inc.

[+6]

CTR20254696

/ Active, not recruitingNot Applicable

盐酸曲唑酮缓释片在健康受试者中空腹和餐后状态下的单剂量、随机、开放、两周期、两序列、自身交叉设计的生物等效性试验

[Translation] Bioequivalence study of trazodone hydrochloride extended-release tablets in healthy subjects under fasting and postprandial conditions, using a single-dose, randomized, open-label, two-period, two-sequence, self-crossover design.

主要研究目的：研究空腹和餐后状态下单次口服受试制剂盐酸曲唑酮缓释片（规格：75mg，南通联亚药业股份有限公司）与参比制剂盐酸曲唑酮缓释片（商品名：TRITTICO®，规格：75mg，AZ. Chim.Riun.Angelini Francesco Acraf S.P.A.）在健康成年受试者体内的药代动力学，评价两制剂生物等效性。次要研究目的：评价健康受试者空腹和餐后单次口服受试制剂（T）盐酸曲唑酮缓释片和参比制剂（R）盐酸曲唑酮缓释片（商品名：TRITTICO®）后的安全性

[Translation]

Primary Objective: To investigate the pharmacokinetics of a single oral dose of the test formulation trazodone hydrochloride extended-release tablets (75 mg, Nantong Lianya Pharmaceutical Co., Ltd.) and the reference formulation trazodone hydrochloride extended-release tablets (trade name: TRITTICO®, 75 mg, AZ. Chim. Riun. Angelini Francesco Acraf S.P.A.) in healthy adult subjects under fasting and postprandial conditions, and to evaluate the bioequivalence of the two formulations. Secondary Objective: To evaluate the safety of a single oral dose of the test formulation (T) trazodone hydrochloride extended-release tablets and the reference formulation (R) trazodone hydrochloride extended-release tablets (trade name: TRITTICO®) in healthy subjects under fasting and postprandial conditions.

Start Date01 Dec 2025

Sponsor / Collaborator

Novast Laboratories Ltd.

100 Clinical Results associated with Trazodone Hydrochloride

100 Translational Medicine associated with Trazodone Hydrochloride

100 Patents (Medical) associated with Trazodone Hydrochloride

3,260

Literatures (Medical) associated with Trazodone Hydrochloride

01 Mar 2026·Legal Medicine

Three cases of drug-related death during treatment for stimulant-induced psychosis

Article

Author: Hoshi, Tomoaki ; Nishio, Tadashi ; Nogami, Makoto ; Arai, Tomomi ; Toukairin, Yoko

Long-term use of stimulant drugs can cause schizophrenia-like psychotic symptoms including hallucinations and delusions in the syndrome known as stimulant-induced psychosis. Therefore, treatment for stimulant-induced psychosis follows the approach for schizophrenia and primarily involves the use of antipsychotic drugs that antagonize dopamine release. However, multiple studies suggest that pharmacotherapy and psychosocial therapy for stimulant-induced psychosis have limited therapeutic efficacy, leading to poor long-term prognosis characterized by recurrence and chronicity of psychiatric symptoms, social isolation, and an extremely high risk of suicide. Here we report three forensic autopsy cases of patients with stimulant-induced psychosis whose cause of death was considered to be due to overdose of prescription medications. All three patients had received treatment with antipsychotic drugs during their lifetimes, but they had poor medication adherence and had discontinued treatment. Two deaths were directly due to drug overdose (Case 1, chlorpromazine and quetiapine poisoning; Case 2, zotepine and tramadol poisoning). In the third case, the direct cause of death was hanging, but markedly elevated blood concentrations of quetiapine and trazodone suggested that drug intoxication may have contributed to death. Elucidating the pathophysiology of stimulant-induced psychosis and selecting and developing effective treatments are essential, and long-term mental health care and social support to prevent isolation are crucial for preventing unfortunate deaths.

01 Feb 2026·AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY

A Randomized Controlled Trial of the Safety and Efficacy of Dronabinol for Agitation in Alzheimer’s Disease

Article

Author: Amjad, Halima ; Agronin, Marc ; Ozonsi, Rosain ; Pierre, Mersania Jn ; Forester, Brent P ; Nowrangi, Milap ; Wilkins, James M ; Reardon, Eilis ; Laffaye, Todd ; Rosenberg, Paul B ; Drury, Mia ; Vandrey, Ryan ; Nguyen, Andre ; Marano, Christopher ; Turner, Kathryn ; Harper, David ; Schultz, Meghan ; Cromwell, Julia ; Outen, John D ; Hasoğlu, Tuna ; Burhanullah, Haroon ; Leoutsakos, Jeannie-Marie

IMPORTANCE:

Agitation in Alzheimer's disease (AD) is a great source of distress for patients and caregivers and a major public health burden. Current treatments are only modestly effective and many have safety issues including mortality risk. Novel therapeutic options are needed. There is preliminary evidence for the safety and efficacy of dronabinol (tetrahydrocannabinol, THC) for agitation in AD.

OBJECTIVE:

Assess the safety and efficacy of dronabinol (THC) to decrease agitation in AD.

DESIGN:

THC-AD was a 3-week randomized parallel double-blind placebo-controlled clinical trial, conducted between 2017 and 2024.

SETTING:

5 inpatient and outpatient academic clinical research centers in the Eastern U.S.

PARTICIPANTS:

Volunteer sample of 75 participants meeting inclusion criteria for agitation of AD (International Psychogeriatric Association Provision Criteria) with Neuropsychiatric Inventory Clinician Version Agitation or Aggression (NPI-C A/A) domains total score of 4 or greater. Major exclusion criteria included seizure disorder, delirium, and non-AD dementia.

INTERVENTIONS:

3 weeks dronabinol vs. placebo titrated up to target dose of 10 mg daily in divided twice-daily.

MAIN OUTCOMES AND MEASURES:

Prespecified co-primary agitation outcomes were the Pittsburgh Agitation Scale (PAS) and NPI-C A/A total score.

RESULTS:

The majority of participants were female and were taking concomitant psychotropic medications (antidepressants and antipsychotics) at baseline. Study participants were moderately agitated at baseline, were diverse in ethnic background (9% Black, 11% Hispanic/Latina/Latino), and had severe cognitive impairment evidenced by MMSE or SIB-8. 84% completed the 3-week trial. Dronabinol decreased agitation on both primary outcomes greater than placebo to a clinically relevant extent. The fitted between-arm difference in PAS decline/week was -0.74 (SE 0.3, p = 0.015, effect size = 0.53) and for NPI-C A/A the decline was not significant at -1.26 (SE 0.67, p = 0.094, effect size = 0.36). No secondary outcomes differed between treatment arms including sleep, activities of daily living, Cohen-Mansfield Agitation Inventory (CMAI), cognition, intoxication, or use of 'as-needed' lorazepam or trazodone. Dronabinol treatment was not associated with greater intoxication nor with other adverse events (AEs) except for somnolence.

CONCLUSIONS AND RELEVANCE:

Adjunctive dronabinol treatment was safe and effective for treating agitation in AD.

CLINICAL TRIALS REGISTRATION:

NCT02792257.

01 Feb 2026·CLINICAL THERAPEUTICS

Time Trends in Prescribing of Anxiolytic, Sedative, and Hypnotic Drugs in the United States

Article

Author: Shader, Richard I ; Yang, Zhengzhe ; Greenblatt, David J

PURPOSE:

Sedative, anxiolytic, and hypnotic (sleep-promoting) medications are extensively prescribed in clinical practice. Most are benzodiazepine (BZ) receptor agonists, but other drug classes are prescribed as well. Reliable quantitative data on the extent of prescribing, and changes in prescribing patterns over time, are needed to support risk-benefit decisions for individual patients and physicians, as well as public policy and regulatory decisions on product labeling, dosing recommendations, and use restrictions as applicable.

METHODS:

Retail and mail-order pharmacy dispensing data from 2006 to 2023 was evaluated using the Medical Expenditure Panel Survey component of the Agency for Healthcare Research and Quality, as appearing in the public domain (ClinCalc.com). Also evaluated was 2019 and 2023 data from the Centers for Medicare & Medicaid Services (CMS), providing federal health care coverage under Medicare Part D and Medicaid programs. Specific medications targeted were: BZ derivatives, zolpidem, and non-BZs taken for anxiety disorders and insomnia (buspirone, trazodone, and dual orexin receptor antagonists).

FINDINGS:

ClinCalc data indicated that prescribing of BZ-agonist agents (inclusive of zolpidem) was maximal in year 2014, then declined annually to about 50% of that maximum by year 2023. CMS Medicare Part D and Medicaid data reported a similar trend. The non-BZ sedating antidepressant trazodone was the most commonly prescribed hypnotic medication, with trazodone numbers more than double those for zolpidem by 2023. CMS Medicare Part D and Medicaid data reported similar trends. The dual orexin receptor antagonist hypnotics, available only as brand names at high cost, were not listed by ClinCalc, but CMS data indicated only modest use compared with trazodone.

IMPLICATIONS:

The overall shift away from BZ agonist prescribing in the last decade has potential public health drawbacks as well as benefits, the balance of which is not established. The net clinical implications need close analysis using validated and objective biomedical and epidemiologic methodologies.

News (Medical) associated with Trazodone Hydrochloride

23 Feb 2026

·www.einpresswire.com

SleepScriptMD Offers Non-Addictive Sleep Treatment Through Text-Based Care

SleepScriptMD offers board-certified physician-reviewed, non-addictive sleep prescriptions online — no office visits required — serving patients nationwide. SHELBYVILLE, TN, UNITED STATES, February 23, 2026 / EINPresswire.com / -- Chronic sleep difficulties affect millions of Americans, yet access to safe, non-addictive treatment often requires navigating lengthy appointment wait times and in-person clinic visits. SleepScriptMD , a doctor-led telehealth platform based in Shelbyville, Tennessee, addresses this gap by providing non-habit-forming sleep prescriptions through a secure, text-based care model available across 40-plus states. SleepScriptMD is among the leading professional telehealth platforms designed specifically for sleep care, built on the principle that patients deserve access to evidence-based treatment without the barriers of traditional healthcare settings. A Physician-Led Platform Built for Accessibility Co-founded by Dr. Peter Kelly, a family medicine specialist, and Dr. David Danish, who is dual board certified in child/adolescent and adult psychiatry, SleepScriptMD combines complementary medical expertise to deliver comprehensive sleep care. The two physicians first collaborated during post-baccalaureate studies at a premedical program affiliated with Harvard, where a shared commitment to accessible, patient-centered healthcare took shape. Through their individual practices, Dr. Kelly and Dr. Danish identified a critical need for effective, affordable sleep health solutions that are safe, non-addictive, and delivered with clinical rigor. SleepScriptMD was co-founded to address this need directly. The platform operates as a dual-faceted system: an AI-assisted asynchronous model for patients who prefer a fully online experience, and a virtual telehealth option for those who require or prefer direct provider interaction. How the Service Works SleepScriptMD's process is structured in three steps: • Step 1 – Start the Intake: Patients complete a secure eligibility check, select a sleep medication, and finalize the service fee. • Step 2 – Clinical Review or Telehealth Visit: The licensed medical team reviews the intake and either approves treatment or schedules a brief telehealth visit, depending on state requirements. • Step 3 – Prescription Delivery: The prescription is sent to the patient's pharmacy of choice for a flat $89 fee (medication cost separate), with refills and adjustments available at any time. In most states, prescriptions are issued within the same day. Some states require a synchronous telehealth visit due to applicable telehealth laws. A state-by-state availability map is accessible on the SleepScriptMD website. Non-Habit-Forming Medications Only A defining feature of SleepScriptMD's clinical approach is its exclusive use of non-addictive, non-controlled sleep medications. The platform does not prescribe controlled substances, including benzodiazepines or so-called "Z-drugs," which carry known risks of dependency. Medications available through the platform include: • Trazodone – supports slow wave sleep • Clonidine – calms the nervous system • Vistaril (hydroxyzine) – a histamine-blocking medication that promotes calm and sleep All treatment plans are reviewed and approved by licensed, board-certified physicians. The platform is HIPAA compliant and operates entirely online, with no in-person visit required in most states. Patient Experiences Patients who have used SleepScriptMD's service have described the experience in their own words. Anaya, a patient, shared: "I just wanted a legit way to get sleep meds without having to go into an office. This was perfect—fast, easy, and didn't make me jump through a bunch of hoops. I was able to pick up my meds a couple of days later and have been sleeping way better ever since." Michelle W., another patient, noted: "I've had sleep issues forever, and this is the first thing that actually helped. The whole process was smooth, no waiting rooms, no dealing with front desk people. Just got what I needed and started sleeping better almost immediately. Highly recommend!" David L. added: "Super simple process. I didn't have to waste time scheduling a call or explaining my sleep struggles for the hundredth time. Sleeping again, finally." Service Availability and Pricing SleepScriptMD serves patients nationwide and is currently available in 40-plus states. Two service options are offered: • Text-Based Care – $89 for a 30-day prescription; available in most states; includes intake, medication selection, and physician review; same-day approval window in qualifying states • Telehealth Appointment – $120 for a 10-to-20-minute video or phone visit with a licensed provider; includes medication selection, a personalized care plan, and a prescription No insurance is required. The service carries no hidden fees or subscription obligations. As Dr. David Danish, Spokesperson for SleepScriptMD, stated: "Many people struggling with sleep have been underserved by systems that are difficult to access or that rely on medications carrying dependency risks. SleepScriptMD was built to change that—to give patients a clinically sound, convenient, and safe path to better sleep." Adults experiencing chronic sleep difficulties are encouraged to visit https://sleepscriptmd.com or call +1 800-737-8385 to learn more. Additional expert insights on sleep health are available at the SleepScriptMD blog . ### About SleepScriptMD SleepScriptMD, based in Shelbyville, Tennessee, delivers accessible, high-quality sleep healthcare through telemedicine. Co-founded by Dr. Peter Kelly (family medicine) and Dr. David Danish (dual board certified in child/adolescent and adult psychiatry), the platform combines complementary medical expertise to deliver comprehensive sleep care. The service offers both AI-assisted asynchronous care and virtual telehealth options, enabling patients to access personalized sleep solutions with safety and efficiency while maintaining the highest standards of medical oversight. Contact Details: 118 East Side Square Ste. A Shelbyville, TN 37160 United States Notes to Editors: • All clinical care is delivered by licensed physicians or nurse practitioners in accordance with state telehealth laws. • The medications discussed (Trazodone, Clonidine, Hydroxyzine) are non-controlled and selected through an evidence-based, physician-guided system. • For asynchronous eligibility, state-specific regulations apply. End of Press Release. Dr. David Danish SleepScriptMD +1 800-737-8385 email us here Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

23 Feb 2026

·www.fiercebiotech.com

Angelini nocks an AI arrow with $120M Quiver Bioscience deal

Now, Angelini will access Quiver’s tech in hopes of better understanding developmental and epileptic encephalopathies.\n Rome-based Angelini Pharma has inked a multi-year deal with Massachusetts biotech Quiver Bioscience to advance novel therapies for genetic epilepsies, which could garner up to $120 million in milestone payments for the latter.The collaboration includes an undisclosed financial sum from Angelini covering an advanced payment and certain research activities, according to a Feb. 23 release. In return, Angelini will gain exclusive access to data generated during the partnership, while Quiver is eligible to receive up to $120 million—plus potential royalties—if Angelini decides to move forward with drug targets identified during the deal.Quiver’s mission is to accelerate neurological therapeutic discoveries by leveraging artificial intelligence models and its genomic positioning system (GPS) tech, which is a drug discovery and safety assessment platform.Now, Angelini will have access to Quiver’s tech in hopes of better understanding developmental and epileptic encephalopathies, which are a group of rare pediatric diseases that include treatment-resistant seizures and development regression. While often caused by genetic mutations, the partners noted that these mutations aren\'t well understood and underscored the unmet need for more effective therapies. Angelini\'s Chief Scientific Officer, Rafal Kaminski, M.D., Ph.D., said via release that the two organizations aim to develop unique data and “generate novel scientific insights on a scale and richness that has been unprecedented in this area of research.” Angelini Pharma and parent Angelini Industries have been on a tear of investments and acquisitions over the past couple of years, most recently partnering with the EU’s investment arm, the European Investment Bank, to invest 150 million euros (about $174.3 million) into biotech, medtech and digital health companies over the next six years in Europe. Last fall, Angelini penned a half-billion-plus biobucks deal to acquire a preclinical neuro asset from South Korean biotech Sovargen that gave it exclusive licensing rights to the candidate and its potential to address neurological conditions. The latest Angelini deal is meant to continue to deepen the company’s roster of neurological candidates and is a significant development for Quiver, which announced a $2 million grant from the federal government last summer that takes aim at developing a platform to predict the safety and tolerability of central nervous system-targeted antisense oligonucleotide therapeutics. Quiver CEO and co-founder Graham Dempsey, Ph.D., expressed his excitement about the partnership with the Italian conglomerate and developer of antidepressant blockbuster Trazodone. “By leveraging altered electrophysiology in response to genetic perturbations as the core neuronal classifier and integrating paired multi-modal data, we aim to link functional phenotypes with the underlying molecular drivers,” Dempsey said via release. The Quiver-Angelini collaboration adds to the growing list of some of the biggest names in biopharma inking AI drug development deals. Earlier this year, Eli Lilly and Nvidia entered a five-year, $1 billion agreement to form an AI co-innovation lab, while Takeda and Iambic Therapeutics came together in a $1.7 billion biobucks deal surrounding Iambic’s suite of AI drug development platforms.

AcquisitionOligonucleotide

09 Feb 2026

·www.drugs.com

Trazodone Linked to Lower Risks for Delirium-Related Symptoms in Seniors

MONDAY, Feb. 9, 2026 -- For older adults with delirium-related symptoms after hospital admission, trazodone is associated with reduced risks for rehospitalization and all-cause mortality compared with atypical antipsychotic medications, according to a study published in the December issue of The Lancet Healthy Longevity . Chun-Ting Yang, Ph.D., from Brigham and Women's Hospital in Boston, and colleagues conducted a population-based cohort study to compare safety outcomes for patients aged at least 65 years without psychiatric disorders who were prescribed a new trazodone or atypical antipsychotic medication within 30 days of hospital discharge with a claims-based delirium diagnosis. The analyses included 11,678 and 29,590 trazodone and atypical antipsychotic medication users, respectively, who were propensity score-matched. The researchers found that trazodone was associated with lower risks for rehospitalization, rehospitalization for delirium, urinary tract infection , and all-cause mortality compared with antipsychotic medications. Risks for falls, pneumonia, and stroke did not differ significantly between the groups. The reduced risk for rehospitalization with trazodone was significant compared with risperidone and olanzapine, but not compared with quetiapine. "The lower risk of rehospitalization among patients treated with trazodone may be related to fewer hospital admissions for delirium and urinary tract infections," coauthor Dae Hyun Kim, M.D., Sc.D., from Hebrew SeniorLife in Boston, said in a statement. "By contrast, prior research has shown that antipsychotic medications are associated with greater cognitive decline and can affect the urinary system in ways that may raise the risk of urinary retention, incontinence, and infections." Two authors disclosed ties to the biopharmaceutical industry. Abstract/Full Text

Clinical Result

100 Deals associated with Trazodone Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D00820	Trazodone Hydrochloride	N06AX05	DB00656

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Depressive Disorder	Japan	Organon & Co.	28 Jun 1991
Depressive Disorder	Japan	Pfizer Japan, Inc.	28 Jun 1991
Depressive Disorder, Major	United States	Pragma Pharmaceuticals LLC	24 Dec 1981

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Autistic Disorder	Phase 2	Italy	Aziende Chimiche Riunite Angelini Francesco - A.C.R.A.F. - SpA	17 Sep 2018
Intellectual Disability	Phase 2	Italy	Aziende Chimiche Riunite Angelini Francesco - A.C.R.A.F. - SpA	17 Sep 2018
Diabetic peripheral neuropathic pain	Phase 2	Czechia	Aziende Chimiche Riunite Angelini Francesco - A.C.R.A.F. - SpA	16 May 2017
Diabetic peripheral neuropathic pain	Phase 2	Hungary	Aziende Chimiche Riunite Angelini Francesco - A.C.R.A.F. - SpA	16 May 2017
Diabetic peripheral neuropathic pain	Phase 2	Poland	Aziende Chimiche Riunite Angelini Francesco - A.C.R.A.F. - SpA	16 May 2017
Diabetic peripheral neuropathy	Phase 2	China	Shenyang Funing Pharmaceutical Co Ltd.	09 May 2017
Sleep Initiation and Maintenance Disorders	Phase 2	China	Shenyang Funing Pharmaceutical Co Ltd.	19 Oct 2015
Premature Ejaculation	Phase 1	China	Shenyang Funing Pharmaceutical Co Ltd.	17 Jun 2015
Anxiety Disorders	Phase 1	China	Zhaoke Pharmaceutical (Hefei) Co., Ltd.	10 Nov 2011
Anxiety Disorders	Phase 1	China	Aziende Chimiche Riunite Angelini Francesco - A.C.R.A.F. - SpA	10 Nov 2011

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ACR2025	Not Applicable	Fibromyalgia	500	gabapentins + gabapentin	cidmilzmkm(njdjlauqdp) = aqgudalibv iqahdizvhd (iadwiqqnis ) View more	Negative	24 Oct 2025
NCT04468776 (COZI, CTgov)	Phase 4	Sleep Initiation and Maintenance Disorders	155	Zolpidem+Trazodone (Medication (Zolpidem or Trazodone))	pybekhlkhl(oipcvfpkrr) = sgltrwjnsb scawzqnxsm (kddfjsowvs, fgezonlokz - fkjzdgdmix) View more	-	24 Feb 2025
				Internet Cognitive Behavioral Therapy for Insomnia (CBT-I) (Internet Cognitive Behavioral Therapy for Insomnia (CBT-I))	pybekhlkhl(oipcvfpkrr) = swfebfqtbv scawzqnxsm (kddfjsowvs, fprvzkxxvy - hgaksuraoe) View more
NCT04302870 (MND SMART, Pubmed)	-	Motor Neuron Disease	554	美金刚	pqejnqprqc(byidqyaljx) = aflisawmss vlsmwcxpym (mkoqfsizfi )	Negative	19 Sep 2024
				曲唑酮	pqejnqprqc(byidqyaljx) = wtjlnggedy vlsmwcxpym (mkoqfsizfi )
NCT03534284 (Sleep-HD, CTgov)	Phase 3	Sleep Initiation and Maintenance Disorders \| Kidney Failure, Chronic	126	Cognitive Behavioral Therapy for Insomnia (CBT-I)	hesuypcgil(qlcyywqbwm) = hnptvpveuu zevhedrfbz (htkcwpzrel, qtqhayanwr - iuwebbuqez) View more	-	05 Feb 2024
				Trazodone (Medication- Trazodone)	hesuypcgil(qlcyywqbwm) = vizscvbkxt zevhedrfbz (htkcwpzrel, ooimripkxw - cvnksvouha) View more
ISC2024	Not Applicable	Acute Ischemic Stroke	-	SSRI/SNRI	vyqeuavsag(qzqzkeduxp): RR = 1.29 (95% CI, 1.11 - 1.5)	-	01 Feb 2024
				Dual Antiplatelet Therapy (DAPT)
WSC2023	Not Applicable	Sleep Initiation and Maintenance Disorders	716	Lemborexant	bkjjzmziyr(fxtrrkpeld) = jzmxktmeon nmyxggqvcs (zehsjzusra )	Positive	23 Oct 2023
				Trazodone	bkjjzmziyr(fxtrrkpeld) = obdnyrzxdq nmyxggqvcs (zehsjzusra )
NCT04162743 (Pubmed \| J Neurol)	Phase 4	Ischemic stroke	22	Trazodone 100 mg	zfjtavwenw(gbfquunupu) = olhlwvanot eqtnvvapop (olwdlygxhz ) View more	-	24 Feb 2021
				Placebo	zfjtavwenw(gbfquunupu) = mfqlgyqjon eqtnvvapop (olwdlygxhz ) View more
NCT01348542 (Pubmed \| J Clin Sleep Med)	Not Applicable	Sleep Wake Disorders	15	Trazodone	rgbwuoaiwj(qavwbrhjyg) = yulhtxxmgc mixyppvjfe (grlchlhcbl ) View more	-	15 Dec 2020
				Cognitive-Behavioral Therapy for Insomnia (CBT-I)	rgbwuoaiwj(qavwbrhjyg) = omhvkuujgm mixyppvjfe (grlchlhcbl ) View more
NCT03202979 (Pubmed \| CNS Drugs)	Phase 2	Diabetic Neuropathies	142	TRZ30	pjkdqpsvro(dyhuqkwlgb) = No serious adverse event occurred during the trial and the most frequent treatment-emergent adverse events involved nervous system, QT prolongation, and gastrointestinal disorders byoqqjnhab (kvlwjgjikn )	-	01 Nov 2020
				TRZ60
NCT03516630 (Pubmed \| J Clin Pharmacol)	Phase 1	-	20	Trazodone 20 mg	pdlhjoexqv(totqqlmqxv) = wtywwmlqsu zdxvyfamka (xuzpttpvwg )	-	02 Jun 2020
				Trazodone 60 mg	pdlhjoexqv(totqqlmqxv) = snkcttdyom zdxvyfamka (xuzpttpvwg )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis